<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117711">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960569</url>
  </required_header>
  <id_info>
    <org_study_id>Minpharm07052012</org_study_id>
    <nct_id>NCT01960569</nct_id>
  </id_info>
  <brief_title>Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas</brief_title>
  <official_title>Single Centre,Randomized,Phase IV Study to Assess the Topical r-Hirudin (Thrombexx)Efficacy in the Patients With Haematomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MinaPharm Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MinaPharm Pharmaceuticals</source>
  <oversight_info>
    <authority>Egypt: Ministry of Health and Population</authority>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre ,Phase IV , interventional, The study includes :

      200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients  will
      have placebo .

      The patients will be randomized to the active product (arm 1) or to placebo (arm 2).

      The study consists of 4 visits as the following :

        -  Visit 1 : on day 1 to check patient eligibility and also for randomization .

        -  Visit 2 : on day 4 to assess target parameters

        -  Visit 3 : on day 8 to assess target parameters

        -  Visit 4 : on day 16 to assess target parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre ,Phase IV , interventional, The study includes :

      * 200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients  will
      have placebo .

      The patients will be randomized to the active product (arm 1) or to placebo (arm 2).

      The study consists of 4 visits as the following :

        -  Visit 1 : on day 1 to check patient eligibility and also for randomization .

        -  Visit 2 : on day 4 to assess target parameters

        -  Visit 3 : on day 8 to assess target parameters

        -  Visit 4 : on day 16 to assess target parameters

             -  Study objective :Assessment the Efficacy of Topical r-Hirudin in treatment of
                haematomas ,also in resolving of the  associated oedema

             -  Study duration : 6 months

             -  Selection of trial subjects:

      Inclusion Criteria :

        1. Age of patients between 20 and 60 years old.

        2. Patients with all types of haematomas.

      Exclusion Criteria:

        1. Presence of  infected wound requiring hospitalization or surgical intervention.

        2. History of allergy or hypersensitivity to any of the ingredients.

        3. Patients with coagulation disorders like haemophilia.

        4. Patients who are on anticoagulants like Warfarin and Acetylsalicylic acid .

        5. Patients who are taking digestive enzymes like alfa chemotrypsin.

             -  Target parameters :

      1.Size of haematoma.( Measured by ruler) , The ruler will measure the  longest 2
      intersecting line.

      2.Size of oedema : by measurement of oedema circumference

      3.Pain (by Vas score).

      4.Change in colour ( by colour grade scale ) .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Size of haematoma</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment the size of haematoma will be by ruler with unit centimeter(cm) , The ruler will measure the longest 2 intersecting line.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Size of oedema</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment the size of oedema will be by measurement the circumference in unit centimeter(cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Pain</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of pain severity will be by Vas score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Colour</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of colour will be by colour grade scale , A=Bluish red , B=Blue ,C= Faint</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas</condition>
  <arm_group>
    <arm_group_label>Arm 1 : active product (Thrombexx)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 : Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active product ( Thrombexx) assigned to arm 1</intervention_name>
    <description>Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete</description>
    <arm_group_label>Arm 1 : active product (Thrombexx)</arm_group_label>
    <other_name>Topical r-Hirudin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo assigned to arm 2</intervention_name>
    <arm_group_label>Arm 2 : Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of patients between 20 and 60 years old.

          -  Patients with all types of haematoma.

        Exclusion Criteria:

          -  Presence of  infected wound requiring hospitalization or surgical intervention.

          -  History of allergy or hypersensitivity to any of the ingredients.

          -  Patients with coagulation disorders like haemophilia.

          -  Patients who are on anticoagulants like Warfarin and Acetylsalicylic acid .

          -  Patients who are taking digestive enzymes like alfa chemotrypsin.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Hafez, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>6th October university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Moneer, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>6th october university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Hafez, Professor</last_name>
    <phone>002 0100 7566299</phone>
    <email>mhafez@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moustafa Sameer, Dr</last_name>
    <phone>002 0100 6016 212</phone>
    <email>msameer@minapharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prof. Mahmoud Hafez</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Moneer, Dr</last_name>
      <phone>002 0100 8608676</phone>
      <email>dr_ahmedmoneer@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mahmoud Hafez, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombexx</keyword>
  <keyword>Topical r-Hirudin</keyword>
  <keyword>Efficacy</keyword>
  <keyword>haematoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
